Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
Department of Radiation Oncology & Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: jherma15@jhmi.edu.
Joseph M
JM
Herman
Katherine Y
KY
Fan
Aaron T
AT
Wild
Laura D
LD
Wood
Amanda L
AL
Blackford
Ross C
RC
Donehower
Manuel
M
Hidalgo
Richard D
RD
Schulick
Barish H
BH
Edil
Michael A
MA
Choti
Ralph H
RH
Hruban
Timothy M
TM
Pawlik
John L
JL
Cameron
Daniel A
DA
Laheru
Christine A
CA
Iacobuzio-Donahue
Christopher L
CL
Wolfgang
D000230:Adenocarcinoma / Q000235:genetics / Q000401:mortality / Q000628:therapy; D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy / Q000379:methods; D000069347:Erlotinib Hydrochloride; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000628:therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D051901:Smad4 Protein / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C497796:SMAD4 protein, human; D051901:Smad4 Protein; D000069347:Erlotinib Hydrochloride